Literature DB >> 2961578

CD4+ helper T cells are required for resistance to a highly metastatic murine tumor.

H J Schild1, B Kyewski, P Von Hoegen, V Schirrmacher.   

Abstract

A role of CD4+ T helper cells in induction of tumor transplant rejection leading to complete regression of a highly metastatic DBA/2 mouse lymphoma was analyzed. Using an anti-CD4 monoclonal antibody (GK1.5) which eliminates T helper cells in vivo and in vitro, we found that CD4+ cells are required for tumor resistance in syngeneic DBA/2 mice or allogeneic but major histocompatibility complex-identical B10.D2 mice. In contrast, in allogeneic C57BL/6 mice tumor rejection was independent of CD4+ cells. An analogous requirement for immune CD4+ cells for in vitro induction of CD8+ tumor-specific cytotoxic T cells was found in these respective strains. The requirement for immune CD4+ cells in vitro could be replaced by recombinant interleukin 2. These results demonstrate a role of CD4+ regulatory T cells and T-T cell cooperation in the induction of anti-tumor immunity and tumor rejection, and point to possible therapeutic interventions in the afferent phase of anti-tumor immune responses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2961578     DOI: 10.1002/eji.1830171231

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

Review 1.  T cell memory, anergy and immunotherapy in breast cancer.

Authors:  Volker Schirrmacher; Markus Feuerer; Philipp Beckhove; Thorsten Ahlert; Viktor Umansky
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

2.  Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine.

Authors:  B S Sharma; L Balazs; A Jin; J C Wang; W B Jolley; R K Robins
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity.

Authors:  V Schirrmacher; S Leidig; A Griesbach
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice.

Authors:  D J Herzyk; E R Gore; R Polsky; K L Nadwodny; C C Maier; S Liu; T K Hart; A G Harmsen; P J Bugelski
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

5.  Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells.

Authors:  M Radrizzani; M Quaia; B Benedetti; S Andreola; M Vaglini; E Galligioni; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation.

Authors:  H Schild; P von Hoegen; V Schirrmacher
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 7.  New insights into tumor-host interactions in lymphoma metastasis.

Authors:  V Umansky; V Schirrmacher; M Rocha
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

8.  Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells.

Authors:  C Fortis; E Ferrero; C Besana; M Biffi; S Heltai; L Galli; A Borri; A Schoenheit; C Rugarli
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

9.  Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection.

Authors:  K Khazaie; S Prifti; P Beckhove; A Griesbach; S Russell; M Collins; V Schirrmacher
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

10.  A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells.

Authors:  Xuelian Wang; Alessandro D Santin; Stefania Bellone; Sushil Gupta; Mayumi Nakagawa
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.